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ORIGINAL ARTICLE
Duchenne muscular dystrophy (DMD) is a com-
mon X-linked recessive neuromuscular disorder
with a worldwide incidence of one in 3500 male
births.1 Patients usually begin to experience weak-
ness of the calf muscles around 3–5 years of age,
become confined to wheelchair before 12 years
of age, and die early in the third decade of life
from respiratory or cardiac failure. Allelic to DMD,
Becker muscular dystrophy (BMD) is distinguished
from DMD by its delayed onset, later wheelchair-
bound state, and a longer life span.2 DMD/BMD is
caused by mutations in the DMD gene on Xp21.2,
which produces the protein dystrophin. The DMD
gene spans 3000 kb, consists of 79 exons with 
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8 alternative promoters linked to the first exon,
and encodes a 14-kb mRNA.3–6 Because of the
large size of the gene, the majority of identified
mutations (65% of DMD cases) are deletions with
loss of one or more exons. Two deletion “hot spot”
regions have been found near the 5’ end and the
central region around exons 44–53, respectively.7–9
Duplications occur almost anywhere in the gene
and have been observed in 5–10% of DMD/BMD
patients.10–12 The remaining 20–30% cases may be
caused by small mutations including point muta-
tions, microdeletions and microinsertions.13 The
rare condition of two noncontiguous mutations
in the same allele has also been reported.14
Many methods have been used for the detec-
tion of mutations in the DMD gene in DMD/BMD
patients and potential carriers. The commonly used
multiplex polymerase chain reaction (mPCR) tech-
nique offers a simple screening for the 18 exons
most commonly found to be deleted, which is
useful in identifying affected males.15,16 Quanti-
tative Southern blotting, quantitative real-time
PCR, fluorescence in situ hybridization (FISH)
and multiplex amplifiable probe hybridization
(MAPH) have been used to detect both deletions
and duplications in the gene.12,17–21 Linkage study
with intragenic and flanking polymorphic markers,
especially short tandem repeats (STR), has also
been used for carrier status analysis.22 However,
quantitative Southern blotting is labor-intensive
and time-consuming, and quantitative real-time
PCR and MAPH are difficult to perform and
sometimes subject to difficult interpretation. FISH
analysis is useless in identifying most duplications
and cannot detect deletions in regions not covered
by the available probes. Linkage analysis has lim-
itations, such as DNA recombination and non-
informative results due to the lack of a proband.
A new technique for multiplex quantitation
of copy numbers at specific target sequences,
multiplex ligation-dependent probe amplifica-
tion (MLPA), has been reported to be a simple,
rapid and reliable tool in detecting deletions and
duplications of the DMD gene.23–25 It is based
on comparative quantitation of hybridized probes
that are amplified by PCR with a single pair of
universal primers. The number of ligated oligo-
nucleotide products is proportional to the amount
of original target DNA. The PCR fragments of dif-
ferent lengths can be separated and quantitated in
an automated capillary DNA sequencer. Therefore,
it allows interrogation of gene dosage at multiple
target loci in a single reaction.
In this study, we employed MLPA analysis to
detect deletions and duplications of the dystrophin
gene in our patients and potential carriers and
compared the frequencies and locations of the
mutations to those of previous reports.
Materials and Methods
DNA samples from 89 consecutive unrelated
DMD/BMD male patients (group I) and another
13 consecutive unrelated potential female carriers
(group II) (13 patients’ mothers) from a total of
102 families were recruited in this study. All these
subjects were local Taiwanese. Diagnosis was based
on clinical presentations, electromyography, mus-
cle biopsy and markedly elevated serum creatine
kinase levels.2 All subjects were referred to the
laboratories for diagnostic testing or for assess-
ment of their carrier status without previous tests
for DMD gene deletions or duplications else-
where. This study was performed retrospectively
and approved by the Institutional Review Board.
Genomic DNA was extracted, using standard pro-
cedures from peripheral blood samples obtained
by venipuncture.
mPCR analyses
For mPCR screening for deletions, two sets of PCR
were used to detect common deletion of 18 exons
(Set I: 4, 8, 12, 17, 19, 44, 45, 48, 51; Set II: 1, 3,
6, 13, 43, 47, 50, 52, 60), as described earlier,
with slight modifications.15,16 The PCR products
were separated on 3% agarose gel.
MLPA analyses
MLPA was performed using the MLPA DMD kit
(SALSA MLPA KIT P034/P035 DMD/Becker, MRC-
Holland, Amsterdam, The Netherlands). The two
kits contained one MLPA probe each for the 79
DMD exons and a probe for the alternative exon
1:DP427C. In each probe mix, five control probes
for other chromosome X sequences were included,
in addition to the 40 DMD specific probes. Details
of the probe sequences and gene loci are shown on
the website (http://www.mrc-holland.com).
MLPA analysis was carried out following the
manufacturer’s protocol (MRC Holland). Briefly,
50–500 ng DNA was denatured (98°C, 5 minutes)
and hybridized with the probe set overnight at
60°C with the SALSA probe mix P034 (DMD
exons 1–10, 21–30, 41–50 and 61–70) and SALSA
probe mix P035 (DMD exons 11–20, 31–40,
51–60, 71–79, and DP427C). Ligation was per-
formed with ligase-65 enzyme at 54°C for 15 min-
utes. The reactions were inactivated by incubation
at 98°C for 15 minutes. PCR was performed with
the specific SALSA FAM PCR primers for 35 cycles
(95°C for 30 seconds; 60°C for 30 seconds; 72°C
for 1 minute). The PCR products were analyzed
in a capillary DNA sequencer (ABI PRISM 3100;
Applied Biosystems, Foster City, CA, USA) with
Genescan 3.7 Software (Applied Biosystems). One
microliter of each PCR product was mixed with
0.5 μL of Genescan-Rox 500 size standard and
8.5 μL of deionized formamide. The analysis time
was 60 minutes using a 36 cm capillary at 60°C.
Three healthy males and three healthy females
without a family history of dystrophinopathies
were included in the analysis as controls.
The peaks obtained after capillary electrophore-
sis could easily be identified and assigned to spe-
cific exons on the basis of their different lengths.
The relative peak area (RPA) of each probe was
obtained by dividing each measured peak area
(As) by the sum of the area of all 45 peaks (ΣAs)
(including five control probes) of that sample.
To obtain the relative peak ratio (RPR), the RPA
(As/ΣAs) was then divided by the mean RPA of
the corresponding probe obtained from the three
control DNA samples of the same sex. The inter-
pretation of the RPR of the amplified probes was
analyzed using a Microsoft Excel template (Rex-
MLPA; http://leedsdna.info/science/dosage/REX-
MLPA/REX-MLPA.htm). A deletion of one or more
exons resulted in a complete loss of one or 
more corresponding peaks in male patients and
a 35–65% reduction of the RPR of the expected
value in the female carriers (Figure 1A–C). Dupli-
cations led to an approximately 200% RPR in
male patients and an approximately 150% ex-
pected RPR in female carriers (Figure 1A, 1D and
1E). Identified deletions and duplications were
taken as reliable when they involved two or more
adjacent exons or were confirmed by mPCR analy-
sis. Apparent single exon deletions or duplica-
tions were considered to be confirmed in male
patients when the corresponding exon failed to
amplify with primer pairs different from those
used in MLPA in cases of single exon deletion
and/or when the same deletion or duplication was
shown in other family members. For subjects with
the same patterns of deletion or duplication, an
intragenic STR analysis of the DMD gene was
employed to exclude possible relatedness.
Results
MLPA analysis was informative in 60.7% (54/89)
of male patients. In group I, MLPA identified
deletions of the DMD gene in 36.0% (32/89) of
the 89 male patients, whereas mPCR detected dele-
tions in 30.3% (27/89) of these samples. All 27
patients with deletions found by mPCR were iden-
tified by MLPA. MLPA revealed a deletion in five
male patients with negative results by mPCR and
showed a larger deletion in 12 male patients, which
could not be detected by the previous mPCR
(Table). The four single exon deletions detected
only by MLPA were confirmed in subsequent uni-
plex PCR of the corresponding exons. MLPA de-
tected exon duplications in 24.7% (22/89) of the
patients. One patient (MD012C) had a complex
rearrangement involving a duplication of two sep-
arate regions (duplication exons 45–48 and dupli-
cation exons 51–55). This result was confirmed by
identification of the same mutation in the carrier
females of the family. In group II, four (30.8%,
4/13) deletions and four (30.8%, 4/13) duplica-
tions of exon(s) were detected in the 13 potential
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female carriers. One carrier (MD010E) also had a
complex aberration of duplications in exons 45–48
and exons 51–55, which was similar to a patient
from another family (MD012C). The intragenic
STR analysis was performed and excluded the 
genetic relatedness of these two subjects.
In this series, deletions were identified in 35.3%
(36/102) of affected families, whereas duplications
were detected in 25.5% (26/102) of the affected
families. There were no ambiguous results in our
study. The deletions were localized on the two
reported deletion “hot spot” regions with 29.2%
(21/72) and 58.3% (42/72) of deletion break-
points located at introns 0–20 and introns 41–60,
respectively. The duplications of exons also showed
two relative “hot spots” near the two deletion
H.L. Hwa, et al
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Figure 1. Relative peak ratio (RPR) of multiplex ligation-dependent probe amplification products of different conditions. (A) Normal control
(with all ratios close to 1). (B) Male patient with an exon 22 deletion (MD011C, with an absence of the peak of exon 22). (C) Female carrier
with a deletion of exons 49–50 (GM056A, with a RPR of exons 49 and 50 around 0.5). (D) Female carrier with duplication on exons 42–44
(GM058A, with a RPR of exons 42, 43, and 44 around 1.5). (E) Male patient with duplication of exons 8 and 9 (MD008D, with a RPR of
exons 8 and 9 around 1.9). Black bar = control probe; gray bar = exon probe.
“hot spot” regions, with approximately one third of
them located at the 5’ end and two thirds of them
located at the central region of the gene (Figure 2).
Discussion
Identification of deletions or duplications in a
large gene is important in the diagnosis of dis-
eases like DMD and BMD. MLPA, a novel method
for quantitation of genomic copy numbers, was
performed to detect both deletions and duplica-
tions in the DMD gene. We obtained rapid and
high quality results. MLPA analysis was informa-
tive in 60.7% (54/89) of affected males. In the
remaining 39.3% of patients with negative results
using MLPA, the disease could have been caused
by small deletions, small duplications or point
mutations. We compared the identified deletions
of the MLPA analysis and those of mPCR in 89
male patients. MLPA detected 36.0% (32/89) of
the patients, while mPCR detected 30.3% (27/89).
None of the deletions found by mPCR was missed
by MLPA and MLPA increased the deletion de-
tection rate by 5.7%. However, the percentage
(36.0%) of deletions revealed by MLPA in this
study is lower than that estimated in previous 
reports.7,8,26–28 We observed a 24.7% (22/89) of
DMD gene duplication rate in these patients,
which is higher than the previously reported rate
of 5–10%.10–12 The discrepancies of frequencies
of deletions and duplications in this series com-
pared to the previous reports may have been due
to the proportion of gene deletions or duplications,
which may vary in different populations. A selec-
tion bias in the patient sample was unlikely be-
cause these patients were referred to our institutes
for DMD gene analysis directly from different cli-
nicians without previous tests for DMD gene dele-
tions or duplications elsewhere. A deletion rate of
37.5% and a duplication rate of 12.5% of the
DMD gene have been reported in a group of
southern Chinese patients.29 However, they used
Southern blotting as detection method and there
were only 24 affected families enrolled in their se-
ries. A recent report revealed a different spectrum
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Table. Samples with different results of multiple
polymerase chain reaction (mPCR) and
multiplex ligation-dependent probe
amplification (MLPA) analysis of Duchenne/
Becker muscular dystrophy patients
Case mPCR MLPA
Patients
GM002A ex12-44del ex8-44del
GM014C ex49-52del ex48-52del
GM021A ex12-13del ex10-13del
GM024C ex47-52del ex46-53del
GM027C Neg ex22-29dup
GM030D Neg ex45-48dup
GM033E Neg ex68del
GM042A Neg ex19-44dup
GM043E ex43-44del ex28-44del
GM044E Neg ex19dup
GM046D ex47-51del ex46-51del
GM059C Neg ex2-26dup
GM061A Neg ex2-7dup
GM063E Neg ex20-43dup
GM065C Neg ex45-51dup
GM071D Neg ex42-47dup
GM080A Neg ex64-67dup
GM084C Neg ex45-49dup
MD002D Neg ex2-29dup
MD004G Neg ex50-54dup
MD005D ex8del ex8-9del
MD007B ex3-60del ex1-73del
MD008D Neg ex8-9dup
MD011C Neg ex22del
MD012C Neg ex45-48dup,
ex51-55dup 
MD014D Neg ex45-52dup
MD015C Neg ex45dup
MD017E Neg ex53-55del
MD018C Neg ex19-45dup
MD019C Neg ex8-10dup
MD020D Neg ex18del
MD023C Neg ex51dup
MD024D Neg ex2dup
MD025E Neg ex53del
MD027D Neg ex56-64dup
MD030E ex8-19del ex8-32del
MD031E ex45del ex45-46del
MD032E ex12-17del ex10-17del
MD035C ex47-52del ex46-55del
del = deletion; dup = duplication; ex = exon; neg = negative.
of DMD gene mutations using semiquantitative
multiplex PCR in Hong Kong patients with 34.3%
of patients with deletions and 7.5% of patients
with duplications.28,30 The significantly lower per-
centage of deletions in these patients was con-
cluded to be an ethnic or regional difference.30
Similar to a report by den Dunnen et al,10 the
two “hot spot” regions of duplications of DMD
gene found in this series were near the two deletion
mutation hot spots. Deletions and duplications
may occur during meiosis I and result from mis-
alignment during pairing of the two homologous
chromosomes. If the two chromosomes mismatch,
the unaligned loop may be deleted. If the misalign-
ment remains and the two chromosomes recom-
bine, the result may be an unequal chromosomal
exchange with a deletion in one chromosome and
a duplication in the other.31–33 The duplications
have a significant role in genomic instability and
in the etiology of diseases that are caused by
frameshift or abnormal gene dosage.32 Our find-
ings of similar “hot spot” regions of deletions
and duplications of the DMD gene were compat-
ible with the possible mechanism of occurrence
of a reciprocal recombination. In this series, the
distribution of mutations revealed approximately
one third at the 5’ end and two thirds in the cen-
tral region of the gene for both deletions and du-
plications. It was different from a previous report
with 20% at the 5’ end and 80% in the central re-
gion for deletions and 80% at the 5’ end and 20%
in the central region for duplications.2 The distri-
bution of deletions and duplications may be di-
verse in different populations and ethic groups.
The distribution of the deletion breakpoints has
been analyzed previously. Deletion breakpoints
in introns 0–20 were 21% and in introns 41–60
were 76% in Europeans, whereas deletion break-
points in introns 1–20 were 15% and in introns
41–60 were 85% in Turks.34 In our population,
the distribution of deletion breakpoints, 29.2%
(27/72) in introns 0–20 and 58.3% (42/72) in
introns 41–60, was different from the two popu-
lations referred to above.
MLPA analysis of the DMD gene can provide
useful information for the prenatal genetic coun-
seling of the affected families. Because no effective
treatment is available for these diseases, the iden-
tification of carrier females is critical to prevent the
birth of patients. The MLPA approach detected
H.L. Hwa, et al
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Figure 2. Schematic presentation of the extent of 36 deletions () and 26 duplications () from the 62 unrelated families
with positive results.
the deletions or duplications in 61.5% (8/13) of
potential female carriers in our study. In the other
38.5% (5/13) of females without deletion or du-
plication, the DNA samples may have been from
noncarrier mothers, or the disease may result from
small mutations. When a negative result is revealed
in the mother of a patient with a positive result
with MLAP, the mutation can be assumed to occur
de novo or due to germ cell mosaicism.
MLPA probes covered all 79 exons of the DMD
gene and, therefore, refined the breakpoints of
the deletions which could be missed by mPCR.
In 12 cases, MLPA showed a more extended re-
gion of deletions than mPCR. In another five cases,
deletions were identified by MLPA, which could
not be detected by mPCR. A more accurate deter-
mination of the extent of deletions/duplications
may improve the prediction of disease severity,
and may facilitate the genotype–phenotype 
correlation.2
False-positive MLPA results may be due to the
presence of polymorphisms obstructing the an-
nealing of the probe.23–25,35 Therefore, in samples
with a single exon deletion, uniplex exon ampli-
fication or sequence analysis should be performed
to validate the findings. False-negative MLPA analy-
sis results were reported in a case with a break-
point distal to the ligation probe of exon 48, which
was detected by mPCR.23 In this study of 89 
unrelated male patients, no false-negative cases
were found compared to mPCR. Recently, single
condition amplification/internal primer (SCAIP)
sequencing, detection of virtually all mutations-
single strand (DOVAM-S) conformational poly-
morphisms, and denaturing high-performance
liquid chromatography (DHPLC) have been used
in addition to mPCR and MAPH for the diagno-
sis of DMD/BMD patients.36–38 SCAIP, DOVAM-S,
and DHPLC can detect both deletions and point
mutations, which could be useful in cases with
negative MLPA results. Because of the high inci-
dence of deletion and duplication, MLPA should
be performed as a first-line screening for DMD
gene mutation. In those with negative results,
SCAIP, DOVAM-S or DHPLC may be carried out
to identify other mutations.
In conclusion, MLPA is a powerful tool in
screening deletions and duplications of the DMD
gene, and could be used in routine clinical diag-
nosis. In this series, the percentage of DMD exon
deletions was significantly lower, whereas the
percentage of duplication was higher than those
in the previous reports, based mainly on the data
of Caucasian populations.
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